{"schema_version":"secwatch.filing_event.v1","accession":"0001640455-23-000003","form_type":"8-K","ticker":null,"cik":"0001640455","company_name":"Jounce Therapeutics, Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.960000+00:00","generated_at":"2026-06-20T19:41:08.316201+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jounce Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance","bullets":["Received Nasdaq deficiency letter on Dec 29, 2022; bid price below $1.00 for 30 consecutive business days.","Has until June 27, 2023 to regain compliance; closing bid must be ≥$1.00 for 10 consecutive business days.","May consider reverse stock split or transfer to Nasdaq Capital Market if not compliant by deadline.","Failure to regain compliance could lead to delisting; appeal rights exist but no assurance of success."],"urls":{"canonical":"https://secwatch.observer/filing/0001640455-23-000003","json":"https://secwatch.observer/filing/0001640455-23-000003.json","markdown":"https://secwatch.observer/filing/0001640455-23-000003.md","text":"https://secwatch.observer/filing/0001640455-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000003/0001640455-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000003/jnce-20221229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:41:08.316201+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0d9445222634a4a37a439ff2702f3a69c1e4add0","claim":"Jounce Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"December 29, 2022, Jounce Therapeutics, Inc., a Delaware corporation (the “Company”), received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with N","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1640455/000164045523000003/0001640455-23-000003-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}